Currently, therapeutics targeting regulation of MMP-TIMP balance in SSc have not successfully translated into clinical settings despite considerable effectiveness in pre-clinical models, with a lack of ongoing clinical trials. The gene discussed is TIMP1; the disease is systemic sclerosis.